Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQPJXT)

• Drug Name: OSU-53 Drug Info
• Synonyms: CHEMBL597622; 1290069-19-0; n-{4-[3-(1-methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-phenyl}-4-nitro-3-trifluoromethyl-benzenesulfonamide; SCHEMBL1615001; BDBM50503138

Indication

Disease Entry	ICD 11	Status	REF
Triple negative breast cancer	2C60-2C65	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 45378798
  TTD Drug ID: DMQPJXT

Molecule-Related Drug Atlas

Drug(s) Targeting AMP-activated protein kinase (AMPK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acadesine	DM1RMF5	Diabetic complication	5A2Y	Phase 3	[3]
MB-11055	DM3RBJW	Fatty liver disease	DB92.Z	Phase 2	[4]
Imeglimin	DMMQFG2	Diabetic complication	5A2Y	Phase 2	[5]
PXL-770	DMNSRY7	Non-alcoholic fatty liver disease	DB92	Phase 2	[6]
ENERGI-F701	DMMIHSO	Alopecia	ED70	Phase 2	[7]
O-304	DMXM34I	Type 2 diabetes	5A11	Phase 2	[8]
IM156	DM4MY9C	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
Phenformin	DMQ52JG	Diabetic complication	5A2Y	Withdrawn from market	[10]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[11]
PMID23639540C13a	DMLXOAQ	Discovery agent	N.A.	Investigative	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
AMP-activated protein kinase (AMPK)	TTLAFZV	AAPK1_HUMAN; AAKB1_HUMAN; AAKG1_HUMAN	Activator	[2]

References

• [1] Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. J Biol Chem. 2011 Nov 11;286(45):39247-58.
• [2] A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth. J Clin Endocrinol Metab. 2015 May;100(5):E748-56.
• [3] Acadesine, an adenosine-regulating agent with the potential for widespread indications. Expert Opin Pharmacother. 2008 Aug;9(12):2137-44.
• [4] Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase.Mol Pharmacol.2007 Jul;72(1):62-72.
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032542)
• [6] Clinical pipeline report, company report or official report of Poxel SA.
• [7] Clinical pipeline report, company report or official report of Energenesis Biomedical.
• [8] Clinical pipeline report, company report or official report of Betagenon.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Complementary regulation of TBC1D1 and AS160 by growth factors, insulin and AMPK activators. Biochem J. 2008 Jan 15;409(2):449-59.
• [11] Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
• [12] Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.